Maintenance bacillus Calmette-Guerin immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: A randomized Southwest Oncology Group study

Journal of Urology

Volumn 163, Issue 4, 2000, Pages 1124-1129

  Lamm, Donald L ^a   Blumenstein, Brent A ^b   Crissman, John D ^b   Montie, James E ^b   Gottesman, James E ^b   Lowe, Bruce A ^b   Sarosdy, Michael F ^b   Bohl, Robert D ^b   Grossman, H Barton ^b   Beck, Thomas M ^b   Leimert, Joseph T ^b   Crawford, E David ^b  

^a Southwest Oncology Group   (United States)

^b NONE

Author keywords

Bladder; Bladder neoplasms; Carcinoma; Carcinoma in situ; Immunotherapy; Transitional cell

Indexed keywords

BCG VACCINE; DOXORUBICIN; MITOMYCIN;

ARTICLE; BLADDER CARCINOMA; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECURRENCE RISK; SURVIVAL TIME; TRANSITIONAL CELL CARCINOMA;

EID: 0034105381     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(05)67707-5     Document Type: Article

References (33)

1. Herr, H. W., Laudone, V. P., Badalament, R. A. et al: Bacillus Calmette-Guerin therapy alters the progression of superficial bladder cancer. J Clin Oncol, 6: 1450, 1988
2. Lamm, D. L.: Long-term results of intravesical therapy for superficial bladder cancer. Urol Clin North Am, 19: 573, 1992
3. Pawinski, A., Sylvester, R., Kurth, K. H. et al: A combined analysis of European Organization for Research and Treatment of Cancer, and Medical Research Council randomized clinical trials for the prophylactic treatment of stage TaT1 bladder cancer. J. Urol, 156: 1934, 1996
4. Lamm, D. L., Blumenstein, B. A., Crawford, E. D. et al: A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guérin for transitional-cell carcinoma of the bladder. N Engl J Med, 325: 1205, 1991
5. Lamm, D. L., Blumenstein, B. A., Crawford, E. D. et al: Randomized intergroup comparison of bacillus Calmette-Guerin immunotherapy and mitomycin C chemotherapy prophylaxis in superficial transitional cell carcinoma of the bladder: a Southwest Oncology Group study. Urol Oncol, 1: 119, 1995
6. Reichert, D. F. and Lamm, D. L.: Long term protection in bladder cancer following intralesional immunotherapy. J Urol, 132: 570, 1984
7. Lamm, D. L.: Bacillus Calmette-Guérin immunotherapy for bladder cancer. J Urol, 134: 40, 1985
8. Hudson, M. A., Ratliff, T. L., Gillen, D. P. et al: Single course versus maintenance bacillus Calmette-Guerin therapy for superficial bladder tumors: a prospective, randomized trial. J Urol, 138: 295, 1987
9. Badalament, R. A., Herr, H. W., Wong, G. Y. et al: A prospective randomized trial of maintenance versus nonmaintenance intravesical bacillus Calmette-Guerin therapy of superficial bladder cancer. J Clin Oncol, 5: 441, 1987
10. Prentice, R. L.: Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med, 8: 431, 1989
11. Pocock, S. J. and Simon, R.: Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics, 31: 103, 1975
12. Rubinstein, L. V., Gail, M. H. and Santner, T. J.: Planning the duration of a comparative clinical trial with loss to follow-up and a period of continued observation. J Chronic Dis, 34: 469, 1981
13. Fleming, T. R., Harrington, D. P. and O'Brien, P. C.: Designs for group sequential tests. Control Clin Trials, 5: 348, 1984
14. Cox, D. R. and Oakes, D.: Analysis of Survival Data. New York: Chapman and Hall, 1984
15. Lamm, D. L., Sarosdy, M. F., Grossman, H. B. et al: Maintenance vs. nonmaintenance BCG immunotherapy of superficial bladder cancer: a Southwest Oncology Group Study. J Urol, suppl., 143: 341A, abstract 610, 1990
16. Lamm, D. L., Crawford, E. D., Blumenstein, B. et al: Maintenance BCG immunotherapy of superficial bladder cancer: a randomized prospective Southwest Oncology Group Study. J Urol, suppl., 147: 274A, abstract 242, 1992
17. Lamm, D. L., Crawford, E. D., Blumenstein, B. et al: Maintenance BCG immunotherapy of superficial bladder cancer: A randomized prospective Southwest Oncology Group Study. Presented at American Society of Clinical Oncology Annual Meeting, San Diego, California, May 17-19, 1992
18. Rawls, W. H., Lamm, D. L., Lowe, B. A. et al: Fatal sepsis following intravesical bacillus Calmette-Guerin administration for bladder cancer. J Urol, 144: 1328, 1990
19. Morales, A., Eidinger, D. and Bruce, A. W.: Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol, 116: 180, 1976
20. Lamm, D. L., Thor, D. E., Harris, S. C. et al: Bacillus Calmette-Guerin immunotherapy of superficial bladder cancer. J Urol, 124: 38, 1980
21. Pinsky, C. M., Comacho, F. J., Kerr, D. et al: Treatment of superficial bladder cancer with intravesical BCG. In: Immunotherapy of Human Cancer. Edited by W. D. Terry and S. T. Rosenberg. North Holland, New York: Elsevier, pp. 309-313, 1982
22. Flamm, J.: Long-term versus short-term doxorubicin hydrochloride instillation after transurethral resection of superficial bladder cancer. Eur Urol, 17: 119, 1990
23. Huland, H., Klöppel, G., Feddersen, I. et al: Comparison of different schedules of cytostatic intravesical instillations in patients with superficial bladder carcinoma: final evaluation of a prospective multicenter study with 419 patients. J Urol, 144: 68, 1990
24. Pagano, F., Bassi, P., Milani, C. et al: A low dose bacillus Calmette-Guerin regimen in superficial bladder cancer therapy: is it effective? J Urol, 146: 32, 1991
25. Blumenstein, B. A.: Editorial comment. J Urol, 156: 1940, 1996
26. Palou, J., Laguna, P., Algaba, F. et al: High grade superficial transitional cell carcinoma of the bladder and/or CIS treated with BCG: Control vs. maintenance treatment. Br J Urol, suppl., 80: 32, 1997
27. Ratliff, T. L., Haaff, E. O. and Catalona, W. J.: Interleukin-2 production during intravesical bacille Calmette-Guerin therapy for bladder cancer. Clin Immunol Immunopathol, 40: 375, 1986
28. DeBoer, E. C, De Jong, W. H., Steerenberg, P. A. et al: Induction of urinary IL1, IL2, IL6 and TNF during intravesical immunotherapy with BCG in superficial bladder cancer. Cancer Immunol Immunother, 33: 306, 1991
29. DeBoer, E. C., De Jong, W. H., Steerenberg, P. A. et al: Induction of urinary interleukin-1 (IL-1), IL-2, IL-6, and tumour necrosis factor during intravesical immunotherapy with bacillus Calmette-Guerin in superficial bladder cancer. Cancer Immunol Immunother, 34: 306, 1992
30. Winters, W. D. and Lamm, D. L.: Antibody responses to Bacillus Calmette-Guérin during immunotherapy in bladder cancer patients. Cancer Res, 41: 2672, 1981
31. Prescott, S., James, K., Hargreave, T. B. et al: Immunopathological effects of intravesical BCG therapy. Prog Clin Biol Res, 310: 93, 1989
32. Lamm, D. L., DeHaven, J. I., Shriver, J. et al: Prospective randomized comparison of intravesical with percutaneous bacillus Calmette-Guerin versus intravesical bacillus Calmette-Guerin for superficial bladder cancer. J Urol, 145: 738, 1991
33. Lüftenegger, W., Ackermann, D. K., Futterlieb, A. et al: Intravesical versus intravesical plus intradermal bacillus Calmette-Guerin: a prospective randomized study in patients with recurrent superficial bladder tumors. J Urol, 155: 483, 1996